William Conkling - 16 Jan 2026 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Reporting relationship: Chief Commercial Officer
Issuer ticker: TARA
Reported as of: 16 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:37:27 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: William Conkling

Key filing fact

William Conkling filed Form 4 for Protara Therapeutics, Inc. (TARA) on 21 Jan 2026.

Key facts

This page summarizes William Conkling's Form 4 filing for Protara Therapeutics, Inc. (TARA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2026, 16:37.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001852018 Primary reporting owner

CONKLING WILLIAM

Relationship: Chief Commercial Officer
Address: C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH 3RD FLOOR, NEW YORK
Signature: William Conkling
Signature date: 21 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARA transaction

Common Stock

Award

Transaction value: $0
Shares: +26,000
Change %: +52%
Price: $0.000000
Shares after: 76,000
Date: 16 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +158,000
Change %
Price: $0.000000
Shares after: 158,000
Date: 16 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 158,000
Exercise price: $5.01
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of January 16, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

Footnote F2

25% of the shares vest on the one year anniversary of January 16, 2026 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.